Evaluation the Anti-Cancer Effect of PEGylated Nano-Niosomal Gingerol, on Breast Cancer Cell Lines (T47D), In-Vitro

Background: Cancer is a significant problem in modern medicine, also is the most common cause of death after cardiovascular diseases, and in need of targeted drug release. Although, chemotherapy is an important candidate in cancer treatment, but it has many side effects on healthy tissues of the body. Therefore, Nano technology is used for specific function, by the least side effects and damage to normal cells. Materials and method: In this study, the pharmacological properties of PEGylated Nano-niosomal Gingerol was examined. Noisome were prepared using reverse phase evaporation method, which contains specific proportion of cholesterol, span60 and polyethylene glycol. Then, PEGylated the prepared formulation by PEG6600. The amount of release and encapsulation of the drug was investigated. The percentage of remains of cancer cell line T47D treated with PEGylated niosomal Gingerol. Results: The average diameter of the nanoparticles, size distribution and zeta potential were reported for PEGylated niosomal sample 35.65 nm, 0.17 and 21 mv, and for PEGylated niosomal drug sample 256.9 nm, 0.23 and 28 mv, respectively. The amount of OD for encapsulated drug was 0.198, also the amount of concentration of the drug which is not encapsulated, was 0.77947 μl of the drug per ml. This value of encapsulated drug was 76.38 percent. Conclusion: The results showed that IC50 of the formulation of PEGylated nanoniosomal Gingerol is less than the standard drug. It seems, the cause of this phenomenon is due to the effect of Polyethylene glycol, in more stability and slower drug release, in the formulation of PEGylated niosome. Also, Polyethylene glycol makes increase in the drug dealing and its greater influence with the target cell. In this study, more than 76% of the Gingerol drug in PEGylated nanoniosomal formulation were enclose. Also, we could reduce the amount of drug release, as much as possible.